Cargando…

Analysis of a beta-lactam allergy assessment protocol challenging diverse reported allergies managed by an antimicrobial stewardship program

OBJECTIVE: To assess the safety and efficacy of a novel beta-lactam allergy assessment algorithm managed by an antimicrobial stewardship program (ASP) team. DESIGN: Retrospective analysis. SETTING: One quaternary referral teaching hospital and one tertiary care teaching hospital in a large western P...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacobs, Max W., Bremmer, Derek N., Shively, Nathan R., Moffa, Matthew A., Trienski, Tamara L., Carr, Dustin R., Buchanan, Carley A., Walsh, Thomas L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523545/
https://www.ncbi.nlm.nih.gov/pubmed/37771740
http://dx.doi.org/10.1017/ash.2023.432
Descripción
Sumario:OBJECTIVE: To assess the safety and efficacy of a novel beta-lactam allergy assessment algorithm managed by an antimicrobial stewardship program (ASP) team. DESIGN: Retrospective analysis. SETTING: One quaternary referral teaching hospital and one tertiary care teaching hospital in a large western Pennsylvania health network. PATIENTS OR PARTICIPANTS: Patients who received a beta-lactam challenge dose under the beta-lactam allergy assessment algorithm. INTERVENTIONS: A beta-lactam allergy assessment protocol was designed and implemented by an ASP team. The protocol risk stratified patients’ reported allergies to identify patients appropriate for a challenge with a beta-lactam antibiotic. This retrospective analysis assessed the safety and efficacy of this protocol among patients receiving a challenge dose from November 2017 to July 2021. RESULTS: Over a 45-month period, 119 total patients with either penicillin or cephalosporin allergies entered the protocol. Following a challenge dose, 106 (89.1%) patients were treated with a beta-lactam. Eleven patients had adverse reactions to a challenge dose, one of which required escalation of care to the intensive care unit. Of the patients with an unknown or low-risk reported allergy, 7/66 (10.6%) had an observed adverse reaction compared to 3/42 (7.1%) who had an observed reaction with a reported high-risk or anaphylactic allergy. CONCLUSIONS: Our implemented protocol was safe and effective, with over 90% of patients tolerating the challenge without incident and many going on to receive indicated beta-lactam therapy. This protocol may serve as a framework for other inpatient ASP teams to implement a low-barrier allergy assessment led by ASP teams.